Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Behandling af svær astma med biologiske lægemidler hos børn og unge

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Metastaserende basalcellekarcinom

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Endoskopisk behandling af hydrocefalus

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Intracerebral hæmoragi tolv dage efter vaccination med ChAdOx1 nCoV-19

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Selvskade er et stigende problem, men der er håb forude

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. Methods for collecting upper respiratory tract specimens for COVID-19 diagnostics

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  1. Maternal 17q21 genotype influences prenatal vitamin D effects on offspring asthma/recurrent wheeze

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Fish Oil Supplementation in Pregnancy and Neurodevelopment in Childhood-A Randomized Clinical Trial

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. High-Dose Vitamin D During Pregnancy and Pathway Gene Polymorphisms in Prevention of Offspring Persistent Wheeze

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Characteristics and Mechanisms of a Sphingolipid-associated Childhood Asthma Endotype

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. Cost of Illness in Young Children: A Prospective Birth Cohort Study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

Prerequisites for successful treatment of severe asthma in children and adolescents with biological drugs are: 1) systematic assessment, excluding and treating other causes of lack of asthma control, 2) immunological phenotyping of the patient, and 3) choice of biological drug targeting the specific disease mechanism. Anti-immunoglobulin (Ig) E and anti-interleukin (IL)-5 have a clinically relevant effect reducing exacerbation rate, but there is still a need for studies in children and adolescents being treated with anti-IgE and anti-IL-5 as well as newer biological drugs, which affect lung function, asthma control and quality of life.

Bidragets oversatte titelBiological drugs for treatment of children and adolescents with severe asthma
OriginalsprogDansk
TidsskriftUgeskrift for Laeger
Vol/bind181
Udgave nummer6
ISSN0041-5782
StatusUdgivet - 4 feb. 2019

    Forskningsområder

  • Adolescent, Anti-Asthmatic Agents/therapeutic use, Antibodies, Monoclonal, Humanized, Asthma/drug therapy, Biological Products/therapeutic use, Child, Humans, Omalizumab, Quality of Life

ID: 62086934